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Abstract
Background: Artemisinin-based combination therapy (ACT) is presently recommended by the World Health
Organization as first-line treatment for uncomplicated Plasmodium falciparum malaria in several countries, as a
mean of prolonging the effectiveness of first-line malaria treatment regimens. A three-day course of artesunate-
mefloquine (4 mg/kg body weight once daily for three consecutive days, plus 15 and 10 mg/kg body weight
mefloquine on the first and second days) has been adopted by Malaria Control Programme of Thailand as first-line
treatment for uncomplicated falciparum malaria all over the country since 2008. The gametocytocydal anti-malarial
drug primaquine is administered at the dose of 30 mg (0.6 mg/kg) on the last day. The aim of the present study
was to assess patient compliance of this combination regimen when applied to field condition.
Methods: A total of 240 patients (196 males and 44 females) who were attending the malaria clinics in Mae-Sot,
Tak Province and presenting with symptomatic acute uncomplicated falciparum malaria, with no reappearance of
Plasmodium vivax parasitaemia during follow-up were included into the study. The first dose of the treatment was
given to the patients under direct supervision. All patients were given the medication for self-treatment at home
and were requested to come back for follow-up on day 3 of the initial treatment. Baseline (day 0) and day 3 whole
blood mefloquine and plasma primaquine concentrations were determined by high performance liquid
chromatography.
Results: Two patients had recrudescence on days 28 and 35. The Kaplan-Meier estimate of the 42-day efficacy rate
of this combination regimen was 99.2% (238/240). Based on whole blood mefloquine and plasma primaquine
concentrations on day 3 of the initial treatment, compliance with mefloquine and primaquine in this three-day
artesunate-mefloquine combination regimen were 96.3% (207/215), and 98.5% (197/200), respectively. Baseline
mefloquine and primaquine levels were observed in 24 and 16% of the patients.
Conclusion: The current first-line treatment and a three-day combination regimen of artesunate-mefloquine
provides excellent patient compliance with good efficacy and tolerability in the treatment of highly multidrug
resistance falciparum malaria. Previous treatment with mefloquine and primaquine were common in this area.
Background
Malaria chemotherapy is under constant threat from the
emergence and spread of multidrug resistance of Plas-
modium falciparum. Resistance has been observed to
almost all currently used anti-malarials. The extensive
deployment of anti-malarial drugs in the past fifty years
has provided a remarkable selection pressure on malaria
parasites to evolve resistance mechanisms. Due to the
high resistance level of P. falciparum to the most afford-
able drugs, such as chloroquine and sulphadoxine-pyri-
methamine, together with high recrudescence rates with
monotherapy with artemisinin derivatives, artemisinin-
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mended by the World Health Organization as first-line
treatment for uncomplicated P. falciparum malaria in
several countries as a mean of prolonging the effective-
ness of first-line malaria treatment regimens [1-4]. Arte-
misinin derivatives are combined with one of several
longer-acting drugs, i.e., mefloquine, amodiaquine, sul-
phadoxine-pyrimethamine, lumefantrine, and pipera-
quine, which permit elimination of the residual malarial
parasites. Among the ACT regimens, the combination
of artesunate with mefloquine has remained a highly
successful therapeutic regimen in regions habouring the
most resistant isolates worldwide particularly in South-
east Asian coutries, such as Thailand and Cambodia
[5-9]. It is effective and provides reliably rapid response.
The pharmacokinetic advantage of the combination of
artesunate with mefloquine is the long half-life of meflo-
quine (14-21 days), which will eradicate residual para-
sites remaining from the potent, but short, action of
artesunate [10]. In addition, artesunate reduces gameto-
cyte carriage and provides mutual protection for meflo-
quine against the increased level and spread of
resistance [11]. A short course of two or three days is
effective and provide reliably rapid therapeutic
responses.
In Thailand, where multidrug resistant P. falciparum
is at high level, the National Malaria Control Pro-
gramme has adopted artesunate in combination with
mefloquine as first-line treatment for uncomplicated fal-
ciparum malaria since 1995. The first combination regi-
men applied initially only in highly mefloquine
resistance areas (Tak, Kanchanaburi, Chantaburi, Trat
and Mae Hong Son Provinces) was a two-day course of
300 mg (6 mg/kg body weight) artesunate given concur-
rently on the first day with 750 mg (15 mg/kg body
weight) mefloquine, followed by 500 mg (10 mg/kg
body weight) mefloquine at six to eight hours apart,
then 300 mg artesunate on the second day. In 2004, this
combination regimen was adopted to all highly meflo-
quine resistance areas througout the country, whereas in
the low to intermediate resistance areas, the dose of
mefloquine was reduced to only a single dose of 750 mg
on the first day. Recently in 2008, the combination regi-
men at the same total dose of 600 mg artesunate and
1,250 mg mefloquine (given as two split doses of 750
and 500 mg), but with a prolonged duration of three
days has been implemented all over the country. The
gametocytocydal anti-malarial drug primaquine is admi-
nistered at the dose of 30 mg (0.6 mg/kg) on the last
day. It is believed that this regimen will improve the
cure rate and delay anti-malarial drug resistance. The
concern is however, patient compliance when applied to
field condition. The main purpose of the present study
was to investigate patient compliance of the current
three-day course of artesunate-mefloquine as first-line
treatment for uncomplicated falciparum malaria in
Thailand.
Methods
The study was conducted at malaria clinics, Tak Pro-
vinces, during March 2008 - February 2009. Malaria is a
serious imported medical problem in this area with a
peak incidence during May-August and November-Janu-
ary of each year. Most patients are adult males and
approximately 55% are caused by P. falciparum [12].
The study was approved by the Ethics Committee of the
Departement of Disease Control, Ministry of Public
Health of Thailand.
A total of 240 patients (196 males and 44 females)
presenting with symptomatic acute uncomplicated falci-
parum malaria (asexual form parasitaemia over 1,000
per microliter blood), who had no history of liver and
kidney disease and no previous anti-malarial treatment
during the previous four weeks (based on a question-
naire interview), and with no reappearance of P.vivax
parasitaemia during follow-up were recruited into this
study. Median (range) values for age and body weight of
the patients were 27(4-69) years and 52(18-65) kg,
respectively. The study was conducted under the Moni-
toring Programme for Antimalarial Drug Resistance of
the Ministry of Public Health of Thailand. All of the
240 cases were selected based on their residential areas
which would have facilitated the complete follow up.
Written informed consents were obtained from all
patients before study participation.
Prior to treatment (day 0), blood sample (3 ml) was
taken from all patients for determination of mefloquine
and primaquine concentrations. Patients were treated
with a three-day combination regimen of artesunate and
mefloquine. The initial dose of 4 mg/kg body weight
artesunate (200 mg, 4 tablets of 50 mg artesunate,
Atlantic Pharmaceutical Company, Thailand) and 15
mg/kg mefloquine (750 mg, three tablets of 250 mg
mefloquine; Atlantic Pharmaceutical Company, Thai-
land) were given on the first day (dy 0). Then patients
were given artesunate and mefloquine tablets for self-
treatment at home. The dose regimen on day 2 was 4
mg/kg body weight artesunate (200 mg, 4 tablets of 50
mg artesunate) and 10 mg/kg body weight mefloquine
(500 mg, 2 tablets of 250 mg mefloquine). On day 3,
artesunate at the dose of 4 mg/kg body weight was
given with 0.6 mg/kg body weight primaquine (2 tablets
of 15 mg primaquine; Government Pharmaceutical
Organization of Thailand). On day 0, the first dose of
the treatment (four tablets of artesunate and three
tablets of mefloquine) was given under direct supervi-
sion and patient was observed for 30 minutes. If patient
vomits within 30 minute, the drug dosages were
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antipyretic paracetamol, and anti-emetic dimenhydrinate
(Dramamine™) was administered.
Patients were requested to return for follow-up in the
morning of the third day of treatment (day 3), and on
days 7, 14, 21, 28 and 42 or at any time if fever or
symptoms suggestive of malaria developed. At each visit,
a parasite count was performed on a Giemsa-stained
blood film, and a detailed questionnaire for general
symptoms was recorded. Blood samples were taken (3
ml) for determination of mefloquine and primaquine
concentrations on day 3. Whole blood (1 ml) and
plasma (1 ml) samples were stored at -20°C immediately
for the analysis of mefloquine and primaquine.
Patients failing to respond to the three-day regimen of
artesunate-mefloquine were treated with the second-line
treatment for uncomplicated falciparum malaria (qui-
nine plus doxycycline given for seven days). Those who
developed Plasmodium vivax malaria in their peripheral
blood during the follow-up periods were treated with
300 mg (base) of chloroquine to suppress symptoms
and a full course of treatment was given at the end of
the study period (chloroquine 1,500 mg given over 48 h,
followed by 15 mg (base) of primaquine daily for 14
days) and excluded from data analysis.
T h ec l i n i c a lo u t c o m eo fat h r e e - d a yc o u r s eo fa r t e s u -
nate-mefloquine was evaluated in the group of patients
who completed the 42-day follow-up period. The clas-
sification of treatment outcomes was based on an
assessment of the parasitological and clinical outcome
of anti-malarial treatment according to the latest
guidelines of WHO. Accordingly, all patients were
classified as having an Early Treatment Failure, a Late
Clinical Failure, a Late Parasitological Failure, or an
Adequate Clinical and Parasitological Response [13].
Patient compliance to treatment medication was
defined as his/her reliability in using an exact pre-
scribed medication, together with the levels of the
drug taken within the acceptable limits. With the help
of a structured questionnaire, patients were inter-
viewed to obtain information on the number of artesu-
nate, mefloquine and primaquine tablets taken.
Compliance to the treatment regimen was assessed
using Box and Whisker plot by identifying the outlier
whole blood mefloquine and plasma primaquine con-
centrations on day 3 of the initial treatment (1.5-3 box
length apart from upper or lower limit line). Meflo-
quine blood concentrations were measured by high
performance liquid chromatography with UV-detection
(HPLC-UV) according to the method of Kangwang et
al, with quantification limit of 3 ng/ml [14]. Prima-
quine plasma concentrations were measured by high
performance liquid chromatography with UV-detection
(HPLC-UV) according to the method of Na-Bangchang
et al, with quantification limit of 1 ng/ml [15].
Results
All patients had a rapid initial response to treatment
with parasites cleared from peripheral blood within 3
days of an initial dose of artesunate and mefloquine. All
patients completed the 42 day follow-up period. Two
patients had recrudescence on day 28 and 35. The
Kaplan-Meier estimate of the4 2 - d a ye f f i c a c yr a t ew a s
99.2% (95% CI 99.0-99.8). No serious adverse event
(SAE) was reported during the study. Many adverse
events (AE) most likely related to the underlying malaria
disease such as headache, muscle pain and anorexia.
These symptoms disappeared by day 2 or day 3 after the
treatment. Based on questionnaire interview, full com-
pliance of 100% was obtained.
Mefloquine concentrations
Of the 215 patients whose mefloquine concentrations
were measured, 163 (75.8%) had undetectable baseline
mefloquine level, whereas 15 (7.0%), 24 (11.6%), and 13
(6.0%) had concentrations of less than 100, between 100
and 500, and more than 500 ng/ml, respectively [median
(range):42 (0-2,424) ng/ml]. Since mefloquine is a long
half-life drug (14-21 days in patients), the decrease in the
concentrations within three days is insignificant and,
therefore, day 3 concentrations in patients who had mea-
s u r a b l eb a s e l i n ec o n c e n t r a tions were estimated by sub-
traction of baseline concentrations from the measured
day 3 concentrations. Figure 1 represents Box and Whis-
ker plot of whole blood mefloquine concentrations on
day 3 in 215 cases. The upper, mid and lower lines which
represent 1
st,2
nd and 3
rd quatiles were 1,716, 2,359, and
3,059 ng/ml, respectively. Median (range) concentrations
on day 3 were 2,359 (27-10,965) ng/ml, with a 95% confi-
dence interval of 1,977-2,353 ng/ml. There were 10
patients with outlier mefloquine concentrations (1.5-3
box length apart from the upper or lower limit line). Two
had concentrations above the upper limit (10,000 ng/ml),
7 had concentrations below the lower limit (27, 90, 141,
172, 215, 247, 695 ng/ml), and one had undetectable level
of mefloquine (lower than quantification limit). Based on
mefloquine concentrations on day 3 with exclusion of
pharmacokinetic factor, complaince with mefloquine in
this three-day artesunate-mefloquine combination regi-
men was 96.3% (207/215).
Primaquine concentrations
Of the 214 patients whose primaquine concentrations
were measured, 180 (84.1%) had undetectable baseline
primaquine level, whereas 29 (13.6%), 4 (1.9%), and 1
(0.5%) had concentrations of less than 100, between 100
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(range): 0 (0-1,662) ng/ml]. Figure 2 represents Box and
Whisker plot of plasma primaquine concentrations on
day 3 in 200 cases. The upper, mid and lower lines
which represent 1
st,2
nd and 3
rd quatiles were 1,716,
2,359, and 3,059 ng/ml, respectively. Median (range)
concentrations on day 3 were 89 (6-640) ng/ml, with a
95% confidence interval of 75-106 ng/ml. There was no
patient with outlier primaquine concentrations, but
undetecable concentration was observed in three cases.
Whole blood mefloquine concentrations in these cases
were as high as 2,669, 2,964 and 6,703 ng/ml. Based on
primaquine concentrations on day 3 with exclusion of
the pharmacokinetic factor, compliance with primaquine
in this three-day artesunate-mefloquine combination
regimen was 98.5% (197/200). There was no correlation
between the pre-treatment concentrations of mefloquine
and primaquine found in this study.
Discussion
Mefloquine was introduced first as a single-dose therapy
for falciparum malaria in Thailand in 1984, but initial
high cure rates were not sustained. In a proposition to
halt the loss of anti-malarial monotherapies to resistance
in rapid succession, the strategy of ACT with meflo-
quine was developed and was adopted in Thailand in
1994. The current regimen of a three-day combination
of artesunate-mefloquine given in total adult dose of
600 mg (12 mg/kg body weight) artesunate and 1,250
mg (25 mg/kg body weight) mefloquine has been imple-
mented by the Bureau of Vector Borne Disease, Depart-
ment of Disease Control, Ministry of Public Health for
the treatment of acute uncomplicated falciaprum
malaria since 2008. The main objective was to obtain
high cure rate of approaching 100% to prevent the
spread of drug resistance. Prior to 2008, the same total
dose of artesunate-mefloquine was given but as a
shorter course of two days and two split doses of meflo-
quine (1,250 and 750 mg) given on the same day at 6-8
hours apart instead of two separate days as the current
regimen. With the current regimen, in addition to the
achievement of high cure rate, the incidence of vomiting
due to high dose mefloquine and thus treatment failure
is expected to be reduced. Absorption of mefloquine in
Figure 1 Box and Whisker plot of whole blood mefloquine concentrations on day 3 after the initial treatment.M e d i a n ,1
st and 3
rd
quatiles = 2,359, 1,716 and 3,059 ng/ml, respectively. Each individual dots represents the case with outlier concentration below or above 1.5-3
box length.
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acute phase of illness. Splitting the dose of 25 mg/kg
mefloquine improves mefloquine absorption and bioa-
vailability, and thus and the therapeutic response in the
treatment of acute falciparum malaria [16-18].
In the present study, a good initial response was
observed in all patients where parasitaemia was cleared
within three days after the initial dose of artesunate and
mefloquine. The present combination regimen of artesu-
nate-mefloquine was shown to improve the cure rate
from approximately 87% with the 2 day course to 96.3%
in the same study area (Tak province) during the year
2001 to 2002 [7]. There were only two cases with treat-
ment failure (cure rate 99.2%) on day 28, and 35 of
treatment. It appears that the cure of this combination
is still retained after eight years of its use (Ministry of
publc Health, unpublished data). The concern about this
three-day course is patient compliance when adopted as
a public health policy. The aim of the present study was
to assess the patient compliance of the current three-
d a yc o u r s eo fa r t e s u n a t e - m e f l o q u i n ew h e na p p l i e dt o
field condition. As the combination is not a fixed dose
regimen, assessment of blood concentration of only one
combination partner, i.e. mefloquine with long half-life
of 14-21 days [19] may not reflect the real full compli-
ance of the combination regimen. Furthermore, since
the half-lives of artesunate and its active plasma meta-
bolite (dihydroartemisinin) are very short (0.5-2 hr), the
drug would have been cleared from blood before 24
hours until patients returned for follow-up on the third
day of treatment (day 3). Apart from mefloquine, plasma
concentrations of primaquine on day 3 was, therefore,
also used as a marker of patient’s adherence to the
three-day regimen with the assumption that if patients
took primaquine tablets, it was likely that they would
have also taken artesunate tablets on the second and
third day. Several methods have been applied for moni-
toring of compliance to drug treatment particularly in
the treatment of chronic diseases. These included clini-
cal judgement of physician, patient self report, clinical
response, biochemical measures, pill counts, pharmacy
records, electronic medication monitoring devices and
measuring of drug concentrations in blood or plasma
[20-22]. Most methods except the last one suffer from
Figure 2 Box and Whisker plot of plasma primaquine concentrations on day 3 after the initial treatment. Median, 1
st and 3
rd quatiles =
33, 74 and 223 ng/ml, respectively. Each individual dots represents the case with outlier concentration below or above 1.5-3 box length.
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drug concentrations in blood has been applied satisfac-
torily for monitoring of patient compliance to a 2 day
combination regimen of artemether-mefloquine when
adopted to field application [23]. In another case, mea-
surement of drug other than the anti-malarial itself, e.g.
low dose phenobarbital, than the has been applied for
monitoring compliance to short course treatment with
anti-malarial regimens (5 day course of artesunate and 7
day course of the combination quinine-tetracycline)
[24]. The concentrations of artesunate and mefloquine
on day 3 (about 24 hours after the last dose of meflo-
quine and primaquine on day 2) were selected as a time
point for monioring the levels of both drugs. Mefloquine
is a long half-life drug, therefore, whole blood meflo-
quine levels on day 3 after the initial treatment could be
applied for monitoring of compliance to this combina-
tion regimen with good accuracy. Based on mefloquine
and primaquine concentrations on day 3 after the intial
treatment, patient compliance of as high as 96-98% was
achieved when excluding the pharmacokinetic factor
due to poor and variable drug absorption in some cases.
It is noted however that patients realized that they were
participating in a study and may significantly influenced
their behaviour (i.e. better compliance). Using the ques-
tionnaire interview as a tool to evaluate compliance to
the dose regimen, full compliance of 100% was obtained,
which means that about 2-4% of non-compliance was
undetected by this method. One case with undetectable
mefloquine level on day 3 could be definitely classify as
non-compliance. The low levels of mefloquine in the
seven cases could be due either to non-compliance to
the second dose of mefloquine or impaired drug absorp-
tion in each individual as none vomited within the first
hour. In our previous study, patient compliance with a
two-day course of artemether-mefloquine (an initial
dose of 300 mg artemether on the first day, followed by
7 5 0a n d5 0 0m gm e f l o u i n eg i v e no nt h es e c o n dd a ya t
4-6 hours apart) was investigated in the same area of
the country. Median (range) whole blood mefloquine
concentrations following the split doses were deter-
mined on the third day (1 day after the initial dose of
mefloquine) was 2,262 (1,198-3,241) ng/ml. This is con-
sidered relatively low when compared with the concen-
trations observed after three days of an initial dose of
mefloquine [median (range) of 2359 (27-10,965) ng/ml].
For primaquine on the other hand, plasma concentra-
tion on day 3 may not be absolutely a suitable marker
for monitoring of compliance to this combination regi-
men in this field setting as the half-life of primaquine is
relatively short (3.7-9.5 hr) [15]. It has been reported
that plasma concentration of primaquine at 25 hr after a
single oral dose of primaqune is only approximately 10-
15% of the Cmax [15]. The case with undetectable
primaquine concentration could be due to pharmacoki-
netic factors (impaired absorption and/or rapid clear-
ance) and/or genuine non-compliance. Full compliance
of approaching 100% with this short course regimen is
considered excellent when comparing with compliance
to long treatment courses of other regimens, such as a
seven-day course of quinine-tetracycine, where pro-
longed drug administration or a relatively high incidence
of cinchonism contributes to about 71.7% compliance in
the field trials [25]. This excellent compliance to the
treatment regimen may also be due to reduced inci-
dence of adverse effects from mefloquine with the split
dose. A simple pre-packaging system and proper coun-
selling could improve compliance with anti-malarial
drug treatment [6,26,27]. Co-formulation of the drugs
reduces the pill burden and more importantly, elimi-
nates the possibility of patients taking only one compo-
nent of the combination. In one study, pre-packaging
anti-malarial drugs have been shown to improve compli-
ance by approximately 20% in both adults and children
[27]. In addition, there were 50% reductions in cost of
patients, waiting time at dispensaries and drug wastage
at facilities. A new fixed-dose co-formulation of artesu-
nate-mefloquine has been launched by Drugs for
Neglected Diseases Initiative (DNDi), which decreases
the risk of resistance due to compliance factor [28].
Nevertheless, this strategy may have limitation with
regard to practicality of dose adjustment.
It is interesting to note that 24.2 and 15.9% of patients
had mefloquine and primaquine levels at baseline pre-
treatment. Seven% had baseline mefloquine concentra-
tions less than 100 ng/ml, 11.6% had concentrations
between 100 and 500 ng/ml, and 13% had concentra-
tions greater than 500 ng/ml. This implies that patients
may have received previous treatment with mefloquine
longer than 35-48, between 35-48, and within 14 days,
respectively [29]. In one of our previous study, it was
observed that 10.2, 11.5, 6.0 and 1.1% had baseline
whole blood mefloquine concentrations of <100, 100-
500, >500-1,000, and >1,000 ng/ml, respectlvely [30].
The lower incidence of observed baseline primaquine
level could be explained by the short half-life of prima-
quine [15]. High incidence of baseline levels in this
patient population indicates the high rate of malaria
transmission in this area and/or drug resistance. Patients
may have received treatment with artesunate-mefloquine
treatment with or without primaquine (as a gametocyto-
cide for falciparum malaria or as antirelapse for vivax
malaria) from other health services nearby or from ille-
gal anti-malarial drugs available in the markets for the
current or previous malaria episode. There has been no
data on the adherence to the 14-day course of prima-
quine for the treatment of vivax malaria, especially pri-
maquine for the treatment of vivax malaria. There was
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quine for the treatment of vivax malaria. Based on the
prevalence of primaquine levels on admission of greater
than 15%, and when considering the short half-life of
this drug, this would suggest that some may have
received previous treatment with primaquine within a
day before participation in the study. This is of concern
as accumulated high level of mefloquine may aggravate
high incidence of adverse effects especially the serious
neuropsychiatric effect. Based on patients’ interview,
none received previous treatment with any anti-malarial
drug. Measurement of drug levels are, therefore, good
confirmation of previous anti-malarial treatment.
Conclusion
The current first-line treatment three-day combination
regimen of artesunate-mefloquine provides excellent
patient compliance with good efficacy and tolerability in
the treatment of multidrug resistance falciparum malaria
in field setting. Previous treatment with mefloquine and
primaquine was common in this area. The results oba-
tined are useful for the malaria control programme of
Thailand as baseline data for optimization of treatment
regimen for uncomplicated falciparum malaria.
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